Ardelyx Inc (ARDX) - Total Assets
Based on the latest financial reports, Ardelyx Inc (ARDX) holds total assets worth $504.51 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Ardelyx Inc (ARDX) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Ardelyx Inc - Total Assets Trend (2012–2025)
This chart illustrates how Ardelyx Inc's total assets have evolved over time, based on quarterly financial data. Explore ARDX strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Ardelyx Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Ardelyx Inc's total assets of $504.51 Million consist of 76.2% current assets and 23.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.6% |
| Accounts Receivable | $71.85 Million | 14.3% |
| Inventory | $17.73 Million | 3.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Ardelyx Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Ardelyx Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ardelyx Inc's current assets represent 76.2% of total assets in 2025, a decrease from 97.3% in 2012.
- Cash Position: Cash and equivalents constituted 13.6% of total assets in 2025, down from 86.9% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 14.3% of total assets.
Ardelyx Inc Competitors by Total Assets
Key competitors of Ardelyx Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €8.68 Billion |
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩703.48 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
|
USA | $452.70 Million |
|
Tourmaline Bio Inc.
NASDAQ:TRML
|
USA | $269.30 Million |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230
|
China | CN¥1.32 Billion |
Ardelyx Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.49 | 4.12 | 3.23 |
| Quick Ratio | 3.28 | 3.81 | 3.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $272.30 Million | $236.85 Million | $128.71 Million |
Ardelyx Inc - Advanced Valuation Insights
This section examines the relationship between Ardelyx Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.98 |
| Latest Market Cap to Assets Ratio | 2.73 |
| Asset Growth Rate (YoY) | 15.1% |
| Total Assets | $501.60 Million |
| Market Capitalization | $1.37 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Ardelyx Inc's assets at a significant premium (2.73x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Ardelyx Inc's assets grew by 15.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Ardelyx Inc (2012–2025)
The table below shows the annual total assets of Ardelyx Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $501.60 Million | +15.11% |
| 2024-12-31 | $435.75 Million | +46.43% |
| 2023-12-31 | $297.58 Million | +56.57% |
| 2022-12-31 | $190.07 Million | +26.78% |
| 2021-12-31 | $149.91 Million | -25.62% |
| 2020-12-31 | $201.56 Million | -22.41% |
| 2019-12-31 | $259.78 Million | +41.70% |
| 2018-12-31 | $183.33 Million | +16.10% |
| 2017-12-31 | $157.90 Million | -25.91% |
| 2016-12-31 | $213.13 Million | +82.25% |
| 2015-12-31 | $116.95 Million | +3.11% |
| 2014-12-31 | $113.41 Million | +164.34% |
| 2013-12-31 | $42.90 Million | +13.25% |
| 2012-12-31 | $37.88 Million | -- |
About Ardelyx Inc
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on… Read more